Skip to main content
. Author manuscript; available in PMC: 2022 Feb 24.
Published in final edited form as: ACS Appl Mater Interfaces. 2021 Feb 12;13(7):7913–7923. doi: 10.1021/acsami.0c19955

Figure 7.

Figure 7.

A) Schematic depicting dosing schedule for B16F10 tumor treatment model. Both the PLGA/PBAE aAPC and the control group received doses of anti-PD-1 monoclonal antibody i.p. on D4 and D5 and received no adoptive transfer of cells. B) Intravenous PLGA/PBAE aAPC treatment led to a reduction in tumor burden compared to untreated mice. C) Treatment with PLGA/PBAE aAPC extended survival compared to the control group. Error bars in B) and C) represent SEM of 6 replicates, (* = p<0.05).